Found: 13
Select item for more details and to access through your institution.
Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2819, doi. 10.1111/dom.14533
- By:
- Publication type:
- Article
Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 10, p. 2279, doi. 10.1111/dom.14469
- By:
- Publication type:
- Article
Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 10, p. 2783, doi. 10.1007/s13300-021-01140-9
- By:
- Publication type:
- Article
General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01757-z
- By:
- Publication type:
- Article
A unified Bayesian framework for bias adjustment in multiple comparisons from clinical trials.
- Published in:
- Statistics in Medicine, 2024, v. 43, n. 15, p. 2928, doi. 10.1002/sim.10064
- By:
- Publication type:
- Article
376-P: REWIND Data on Obesity and Cardiovascular (CV) Health: Waist-to-Hip Ratio (WHR) Independently Predicted CV Outcomes.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-376-P
- By:
- Publication type:
- Article
680-P: Once-Weekly Dulaglutide 3 mg and 4.5 mg Gastrointestinal Tolerability: Post-hoc Analysis of Incidence and Prevalence in Award-11.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-680-P
- By:
- Publication type:
- Article
673-P: Effect of Once-Weekly Dulaglutide 3.0 and 4.5 mg in Patients with Different Baseline Renal Function: Post-hoc Analysis from the Award-11 Trial.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-673-P
- By:
- Publication type:
- Article
651-P: Higher Doses of Dulaglutide Induce Weight Loss in Patients with Type 2 Diabetes (T2D) Regardless of Baseline BMI: Post-hoc Analysis of AWARD-11.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-651-P
- By:
- Publication type:
- Article
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
- Published in:
- Cardiovascular Diabetology, 2021, v. 20, n. 1, p. 1, doi. 10.1186/s12933-021-01386-4
- By:
- Publication type:
- Article
Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Heatwave duration: Characterizations using probabilistic inference.
- Published in:
- Environmetrics, 2020, v. 31, n. 5, p. 1, doi. 10.1002/env.2626
- By:
- Publication type:
- Article
HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article